Good hair-loss advice around this comparisons & decision-making guide has to separate visible change from camera noise, panic, and marketing. The practical value is in staging the pattern, understanding options, and avoiding promises no one can honestly make from a single image.
My friend Ben, a 31-year-old software engineer in Austin, texted me a screenshot last March. He’d placed two browser tabs side by side: Hims on the left, Keeps on the right. Same drug. Same dose. Different packaging, different pricing tiers, different vibes. “Am I paying extra for the Instagram ads?” he asked. Honestly? Kind of. But the real answer required more than a text back.
Hims and Keeps both prescribe finasteride and minoxidil for androgenetic alopecia. The active ingredients are identical. The FDA-approved doses are identical. What separates them is pricing structure, formulation options, and how much clinical context they bother to give you before checkout. This piece walks through the biology those platforms are treating, what the evidence actually supports, what it costs, and where either service (or both) falls short compared to sitting across from a dermatologist.
The Biology They’re Both Targeting
Pattern hair loss has been formally studied since James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences, which established that androgens drive the recession and crown thinning men dread in their bathroom mirrors. Hamilton noticed that men castrated before puberty never developed the pattern. O’Tar Norwood expanded Hamilton’s staging system in a 1975 Southern Medical Journal paper, giving us the seven-stage classification (plus variants) that dermatologists still use today. It has survived for over 70 years because it’s simple enough to apply consistently while capturing most of the natural variation. The BASP classification proposed in 2007 hasn’t displaced it in routine practice.
The molecular story centers on dihydrotestosterone, or DHT. The enzyme 5-alpha reductase converts testosterone into DHT, which is more potent. In genetically susceptible follicles, DHT binds to the androgen receptor in the dermal papilla and slowly wrecks things over successive hair cycles. The anagen (growth) phase shortens. The telogen (resting) phase lengthens. The follicle itself shrinks. What used to be a thick terminal hair becomes a thin, short, nearly invisible vellus hair. That’s follicular miniaturization. It’s why a Norwood III can still technically have follicles in the temple region; they’re just producing hair too fine to see.
The genetics are polygenic. Yes, the androgen receptor gene sits on the X chromosome, which is why people point at the maternal grandfather. But paternal contributions and autosomal loci matter too, so family history is a rough sketch, not a blueprint.
Two drugs exploit this biology directly. Finasteride inhibits the type II isoform of 5-alpha reductase, lowering scalp DHT. Dutasteride (used off-label for hair loss, approved for benign prostatic hypertrophy) inhibits both type I and type II isoforms, lowers DHT more aggressively, and has shown larger hair density improvements in head-to-head trials. Both Hims and Keeps prescribe finasteride. Neither prescribes dutasteride as a standard offering, which tells you something about how conservative their medical model is.
How a Dermatologist Would Actually Evaluate You
Here’s where telehealth services cut corners, not maliciously, but structurally. A proper dermatology workup per AAD clinical guidelines includes patient history, family history, scalp examination, trichoscopy (dermoscopy of the scalp), and selective lab testing.
Trichoscopy reveals things the naked eye and a selfie camera cannot: caliber variability of 20% or more across hair shafts, yellow dots at empty follicular ostia, density changes in affected versus occipital zones. A telehealth questionnaire with uploaded photos can identify classic pattern loss in many cases. It cannot distinguish early scarring alopecia from diffuse androgenetic alopecia. That distinction matters enormously, because scarring alopecias like lichen planopilaris destroy follicles permanently and need entirely different treatment.
Lab testing is selective, not routine. Ferritin, TSH, vitamin D, and CBC are reasonable when telogen effluvium (stress shedding) is suspected or thinning is diffuse. The AAD does not recommend androgen panels routinely in men with classic pattern loss, because the diagnosis is clinical.
Standardized photography (front, top, sides, back, consistent distance and lighting, reproducible head position) is the unsexy backbone of tracking. It’s far more reliable than staring at your hairline in a bathroom mirror under different lighting every morning and convincing yourself things are worse. For a more granular treatment of staging and assessment, including photographic examples, this comparisons & decision-making guide provides a clinical-grade walkthrough.
What the Evidence Supports (and Doesn’t)
Treatment works best when started early, before follicles are gone rather than just miniaturized. That’s the boring truth nobody wants to hear when they’re Norwood V and Googling “hair regrowth.”
Oral finasteride 1 mg daily has the largest evidence base. The original five-year randomized trial published in the Journal of the American Academy of Dermatology (2002) showed sustained improvements in hair count and patient self-assessment versus placebo. Sexual side effects affect a small percentage of users in randomized trials and are generally reversible on discontinuation. The internet discourse around post-finasteride syndrome is emotionally intense but statistically hard to pin down; the controlled trial data shows low incidence.
Topical minoxidil 5% applied twice daily is FDA-approved over the counter. The mechanism isn’t fully understood but involves potassium channel opening, vasodilation, and a direct follicular effect that prolongs anagen. Response typically becomes visible at three to six months. Here’s the catch: roughly 40 to 60 percent of users see visible improvement in randomized trials. A subset of patients lack sufficient sulfotransferase activity to convert minoxidil to its active form, which partly explains nonresponse.
Low-dose oral minoxidil (0.25 to 5 mg daily) is increasingly prescribed off-label following Vañó-Galván et al.’s 2021 JAAD multicenter study of 1,404 patients. The side-effect profile at low doses is more manageable than the original cardiovascular formulation suggested, though periorbital edema and hypertrichosis are reported.
PRP and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published several smaller randomized trials with positive but variable findings. Reasonable additions; not substitutes for medical therapy.
Hair transplantation (FUE or FUT) is the only intervention that physically redistributes follicles. It’s most appropriate when the loss pattern is stable, donor capacity is adequate, and expectations are realistic. Thinking of it like dental implants is useful: you don’t implant into an unstable foundation, and you need enough donor material to work with.
What It Actually Costs
Generic oral finasteride 1 mg runs $10 to $25 per month at US pharmacies with discount cards, and $5 to $15 through direct-to-consumer telehealth. Branded Propecia still costs $70 to $90 monthly with zero documented clinical advantage. (If you’re paying for the brand name, you’re paying for nostalgia.)
Generic topical minoxidil 5% costs $10 to $30 per month. Branded Rogaine roughly doubles that. Foam and solution are clinically equivalent; foam gets a slight edge among patients who report scalp irritation with the propylene glycol in solution.
Low-dose oral minoxidil in generic form is often under $15 per month. The real cost driver is the prescribing visit: $50 to $150 through telehealth, or potentially covered if you see a dermatologist through insurance.
Hair transplantation in the US runs $4 to $10 per graft for FUE. A typical 2,500 to 3,500 graft case totals $10,000 to $35,000. Turkey prices of $2,000 to $5,000 for similar graft counts reflect labor cost and clinic overhead differences, not necessarily quality differences (though quality varies wildly).
PRP runs $500 to $1,500 per session, with most protocols recommending three to four sessions in the first year plus maintenance. First-year PRP costs can match or exceed an entire year of combination medical therapy. That math alone should give anyone pause.
Insurance generally doesn’t cover pattern hair loss treatment (classified as cosmetic). HSAs and FSAs may cover prescribed medications and physician visits but typically exclude surgical procedures.
Lifestyle Factors: Separating Signal from Noise
Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus matched nonsmokers. If you need one more reason to quit, there it is.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding through telogen effluvium. Repletion in deficient patients reduces shedding. Supplementation in iron-replete patients does nothing for hair density. Don’t pop iron pills prophylactically.
Vitamin D deficiency is more strongly linked to alopecia areata than androgenetic alopecia, though JAAD reviews note that severe deficiency may contribute to hair fragility. Supplement to a normal serum level if deficient; don’t megadose.
Severe acute stress triggers telogen effluvium two to three months after the precipitating event, typically resolving within six to nine months. It may unmask underlying pattern loss that was previously subclinical.
Anabolic steroid use accelerates pattern hair loss in susceptible men through supraphysiologic androgen exposure, with effects that may not fully reverse after discontinuation.
Severe caloric restriction, very low protein intake, and rapid weight loss all reliably produce telogen effluvium. Modest dietary improvements beyond correcting specific deficiencies? Don’t expect visible hair benefits.
When Telehealth Isn’t Enough
Self-management through Hims, Keeps, or any telehealth platform is reasonable for straightforward cases. But several scenarios demand in-person dermatology evaluation.
Sudden, diffuse shedding within the past six months suggests telogen effluvium, not pattern loss, and needs workup for the precipitating cause. Patchy hair loss with smooth, well-circumscribed bald patches suggests alopecia areata, an autoimmune condition with a completely different treatment pathway. Scalp pain, burning, redness, scaling, or visible scarring raises the possibility of scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia) that require prompt diagnosis before more follicles are permanently destroyed. Hair loss in women with menstrual irregularities, acne, or hirsutism warrants endocrine evaluation for PCOS or other androgen excess states. Rapid progression in a young patient (more than one Norwood stage per year) deserves in-person confirmation. And failure to respond to 12 months of documented standard medical therapy warrants reassessment.
The AAD position: any progressive hair loss that concerns the patient is a legitimate reason for dermatology consultation. I’d add my own take: if a telehealth platform makes you feel like the only decision is “subscribe” or “don’t subscribe,” it has failed you as a medical encounter.
FAQs
Should I get a hair transplant if I am in my 20s? Experienced surgeons approach transplantation in the 20s cautiously because the long-term progression pattern isn’t established yet. Medical therapy to stabilize native hair is usually prioritized first.
Do biotin and collagen supplements help with hair loss? Evidence supporting biotin or collagen supplementation in patients without documented deficiency is weak. Worth noting: biotin can interfere with several common lab tests, including thyroid function and troponin assays.
What is shock loss after a hair transplant? Shock loss is temporary shedding of native or transplanted hairs in the weeks following a transplant, typically resolving over three to six months as follicles re-enter the growth phase.
How accurate are AI hair-loss assessment tools? AI-based tools provide reasonable orientation for self-screening but don’t replace dermatologic evaluation. Best used as a starting point for understanding likely stage and treatment options.
Is oral minoxidil better than topical? Low-dose oral minoxidil produces effects comparable to topical with better adherence in many patients. The choice depends on side-effect tolerance and patient preference and should be made with a prescribing clinician.
Does minoxidil work for everyone? Minoxidil produces visible improvement in roughly 40 to 60 percent of users in randomized trials, with response typically emerging at three to six months. Sulfotransferase activity variation partly explains nonresponse.
Can Hims or Keeps diagnose scarring alopecia? No. Photo-based telehealth evaluations cannot reliably identify scarring alopecias, which require trichoscopy and sometimes biopsy. If you have scalp symptoms beyond simple thinning, see a dermatologist in person.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
